Addition of Neostigmine and Atropine to Conventional Management of Postdural Puncture Headache: A Randomized Controlled Trial.
Ahmed Abdelaal Ahmed Mahmoud, Amr Zaki Mansour, Hany Mahmoud Yassin...
https://pubmed.ncbi.nlm.nih.gov/30169405/Actively Recruiting
Led by Mayo Clinic · Updated on 2026-03-23
18
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the use of Neostigmine and Glycopyrrolate to treat post-dural puncture headache PDPH in postpartum women who develop this headache after an accidental dural puncture with a Tuohy needle. The study aims to reduce the number of women with PDPH who need an epidural blood patch EBP, which is the current standard treatment but carries some risks and contraindications. This pilot study builds on earlier findings that suggested these drugs might help reduce headache severity and EBP need. In this study, women with PDPH and a pain score of 4 or higher will receive intravenous infusions of Neostigmine 20 mcgkg and Glycopyrrolate 4 mcgkg over 10 minutes. This treatment is given every 8 hours for up to three doses or until pain is reduced to a score of 3 or less. Alongside the study drugs, patients will also receive standard supportive treatments such as hydration, caffeine, acetaminophen, ibuprofen, and pain medication as needed. Participants are carefully monitored during and after infusions for vital signs and possible side effects like muscle cramps or blurred vision. Participants will be assessed daily in the hospital for headache symptoms, and pain scores will be tracked at multiple time points up to two weeks after treatment. Researchers will monitor the number of women requiring EBP within two weeks, changes in pain levels, and any adverse events. The study includes safety monitoring with frequent blood pressure checks, continuous heart and oxygen monitoring during infusions, and follow-up evaluations to understand treatment effects and safety. Participation continues until headache resolution or decision to receive EBP, with total follow-up lasting up to two weeks after intervention.
CONDITIONS
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Neostigmine + Glycopyrrolate IV (Trial) | Epidural Blood Patch (Current Standard) |
|---|---|---|
| What it is | Combination intravenous therapy with neostigmine (20 μg/kg) and glycopyrrolate (4 μg/kg) given every 8 hours up to three doses for postpartum women who experience PDPH after epidural analgesia. | The injection of the patient’s own blood into the epidural space (typically at or near the original puncture site) to treat PDPH that does not resolve with conservative therapy. |
| Role in trial | Sole investigational intervention evaluated in this single-arm study for PDPH. | Widely regarded as the standard of care for PDPH persistent after initial management; not studied as a direct comparator in this trial. |
| Primary use | To relieve headache symptoms and reduce the need for epidural blood patch in postpartum women with PDPH after dural puncture during epidural analgesia for labor. | To provide rapid and effective relief of PDPH when symptoms do not resolve with supportive measures in postpartum women. |
| How it is given or performed | Both drugs are infused intravenously over 10 minutes, every 8 hours, for a maximum of 3 doses within 48 hours of PDPH onset. | A small volume of the participant's own blood is drawn aseptically and injected into the epidural space, usually in the area of the suspected dural puncture. |
| Evidence status | This combination is under clinical investigation and results for this specific trial are not yet available. Some previous studies have investigated similar regimens. | Numerous studies and reviews support EBP as effective therapy for PDPH, with high rates of symptom relief, although some patients require repeat procedures. |
| Important risks or side effects | Potential risks with neostigmine and glycopyrrolate include bradycardia, arrhythmia, possible increased secretions, and allergic reactions. Specific risks for this combination in PDPH are not fully established. | Risks include infection, back pain, nerve injury, and very rarely, serious complications such as hematoma, acute neurologic dysfunction, or meningitis. |
| Important limitations | Limited published evidence for this exact drug combination in PDPH, especially for postpartum women; uncertain generalizability given small sample sizes and lack of data on long-term outcomes. | EBP is invasive, associated with procedure-specific risks, and may not be effective in all cases; some patients experience persistent or recurring headaches and require repeat procedures. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 hours or until headache improvement
Participants receive intravenous infusions of neostigmine and glycopyrrolate every 8 hours for up to 3 doses to treat post dural puncture headache. They are monitored closely during and after infusions for side effects and pain relief.
Monitoring during each infusion and for 20 minutes after; up to 3 infusions every 8 hours
Duration - 2 weeks
Participants are followed up to assess pain scores and monitor for any adverse events related to treatment over a 2-week period.
Multiple assessments at baseline, 1 hour, 8 hours, 16 hours, 24 hours, 48 hours, 1 week, and 2 weeks after treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ahmed Abdelaal Ahmed Mahmoud, Amr Zaki Mansour, Hany Mahmoud Yassin...
https://pubmed.ncbi.nlm.nih.gov/30169405/Sonya P Mehta, Bart P Keogh, Arthur M Lam
https://pubmed.ncbi.nlm.nih.gov/24310044/Jane A Amorim, Mauro V Gomes de Barros, Marcelo M Valença
https://pubmed.ncbi.nlm.nih.gov/22843225/A F Reynolds, S R Hameroff, C D Blitt...
https://pubmed.ncbi.nlm.nih.gov/7191232/H Flaatten, S Rodt, J Rosland...
https://pubmed.ncbi.nlm.nih.gov/3826597/Amir Abrishami, Joyce Ho, Jean Wong...
https://pubmed.ncbi.nlm.nih.gov/19821409/Mahmoud Daoud, Mohamed Asfour, Syed Mubashirulhassan
https://pubmed.ncbi.nlm.nih.gov/31094823/M G Salem, J C Richardson, G A Meadows...
https://pubmed.ncbi.nlm.nih.gov/2857570/Jie Luo, Shuting Chen, Su Min...
https://pubmed.ncbi.nlm.nih.gov/30573962/R D Cornwall, W M Dolan
https://pubmed.ncbi.nlm.nih.gov/127535/Mayo Clinic
Lead Sponsor